Previous Article | Next Article 
Journal of Virology, September 2000, p. 8183-8187, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Mouse Mammary Tumor Virus Transcription
Enhancers for Hematopoietic Progenitor and Mammary Gland Cells
Share Functional Elements
Frank U.
Reuss1,* and
John M.
Coffin2
Forschungsschwerpunkt Angewandte Tumorvirologie
F0400, Deutsches Krebsforschungszentrum, 69120 Heidelberg,
Germany,1 and Department of Molecular
Biology and Microbiology, Tufts University School of Medicine,
Boston, Massachusetts 021112
Received 27 January 2000/Accepted 31 May 2000
 |
ABSTRACT |
Expression of mouse mammary tumor virus (MMTV)-encoded
superantigens in B lymphocytes is required for viral transmission and pathogenesis. We have previously established a critical role of an
enhancer element within the long terminal repeat (LTR) for MMTV
sag gene expression in B-lymphoid progenitor cells. We now demonstrate enhancer activity of this element in a promyelocytic progenitor cell line. We also map the position of the enhancer within
the U3 region of the MMTV LTR and show that the progenitor cell
enhancer shares functional elements with a previously described mammary
gland-specific enhancer.
 |
TEXT |
Mouse mammary tumor virus (MMTV), a
murine B-type retrovirus, causes a high incidence of mammary gland
carcinoma in infected females (15). MMTV-induced T-cell
lymphomas are observed at a lower incidence. Infectious MMTV is
produced by infected mammary gland epithelial cells and transmitted
from mother to offspring via milk (3, 8). MMTV gene
expression and virus production in mammary gland epithelial cells is
constitutively activated through a mammary gland cell-specific enhancer
element within the proviral long terminal repeats (LTRs)
(14) and is further increased during pregnancy by
receptor-mediated glucocorticoid hormone interaction with
steroid-hormone-responsive elements near the major MMTV promoter. After
passage through the gastrointestinal tract, the virus infects B
lymphocytes, and these cells play an important role in virus spread in
an infected animal (2, 9). MMTV encodes a superantigen (Sag)
which, when it is expressed on the surfaces of B cells or other
antigen-presenting cells, activates a large number of T cells by
interaction with specific T-cell-receptor
-chains (1,
17). The resulting T-cell response in turn stimulates the
infected B cells to proliferate (9) and thus amplifies the
numbers of virus-infected cells (10) and potential target
bystander cells. The subsequent clonal elimination of activated T cells
results in a progressive depletion of a specific T-cell subset during
the course of the infection (11). Infection of mammary gland
epithelial cells completes the viral life cycle.
MMTV can also be genetically inherited in the form of endogenous
proviruses (Mtv proviruses) in the host germ line. Sag
expression from inherited proviruses usually leads to depletion of
T-cell subsets that express reactive T-cell-receptor
-chains
(6) but can also, as in the SJL mouse model of follicular
B-cell lymphoma, induce T-cell-dependent, interleukin (IL)-mediated
proliferation of B-lymphoma cells (22).
The viral sag gene encoding the MMTV superantigen is located
within the 3' viral LTR of a provirus (Fig.
1). The mechanism of MMTV sag
gene expression has been controversial, and a total of four different
promoters have been implicated in superantigen expression
(19). The relative functional significance of putative MMTV
promoters and enhancers for sag gene expression from an
infectious, oncogenic MMTV provirus (21) has been tested by
a major histocompatibility complex class II-independent superantigen
reporter assay on the basis of a recombinant superantigen-luciferase
gene that we developed earlier (19, 20). With this system we
were able to detect sag gene expression in cells of the
B-lymphocyte lineage and to demonstrate that promoters within the 5'
LTR are not required for sag gene expression. We have also
described a transcription enhancer within the viral pol gene
that is necessary for efficient expression of the sag gene
in B-cell lines (19) (Fig. 1). In the B-cell progenitor line
Ba/F3, sag gene expression and general gene expression from
the MMTV LTR require a separate enhancer within the viral LTRs
(20). Our recent data demonstrate expression of the MMTV
sag gene in the myeloid progenitor cell line FDC-P1 (V. A. Tovar Sepulveda, B. Berdel, J. M. Coffin, and F. U. Reuss, submitted for publication). FDC-P1 cells were also found in
electron micrographic experiments to produce MMTV-like virions in a
dexamethasone-dependent fashion from an endogenous provirus. These data
raise the question of whether MMTV gene expression in myeloid
progenitor cells is also regulated by the enhancer in B-cell progenitor
cells that we previously characterized. In the present study we
demonstrate the activity of this enhancer element in the myeloid
progenitor cell line FDC-P1 and show that the transcription enhancers
for hematopoietic progenitor and mammary gland cells share functional elements.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of an MMTV provirus and
regulatory elements for MMTV gene expression. (A) MMTV provirus. The
positions of viral genes (gag, pro,
pol, env, and sag), promoters (filled
squares), LTR and pol gene enhancers (E) (open circles),
functional regions within the LTRs (U3, R, and U5), and the
sag gene are indicated. (B) MMTV LTR. Shown is the LTR of
MMTV strain C3H, with the positions of the mammary gland cell enhancer,
as described by four different labs (7, 12, 14, 24),
represented as solid lines below the LTR. The location of the newly
characterized hematopoietic progenitor cell enhancer from positions
1025 to 761 of the Mtv-1 LTR, corresponding to the
region from positions 1049 to 785 of the C3H LTR, is shown as a
hatched box. The positions of promoters (P) within the LTR, functional
regions (U3, R, and U5), and the transcription start site (+1, arrow)
are indicated.
|
|
The MMTV progenitor cell enhancer is active in B-cell progenitor
and promyelocytic cell lines.
The murine, bone marrow-derived
hematopoietic progenitor cell lines Ba/F3 and FDC-P1 are IL-3 dependent
and nontransformed and represent pro-B and promyelocytic cell types,
respectively. MMTV gene expression in the progenitor B-cell line Ba/F3
depends on the function of an enhancer element within a 548-bp region (nucleotides 9 to 556, positions
1162 to
613) of the
MMTV(Mtv-1) LTR (4) present at the 5' terminus of
the Mtv-1/C3H provirus called hybrid MMTV (20,
21). The corresponding region within the MMTV(C3H) LTR
(13) at the 3' position of the reporter provirus has the
same stimulatory effect. To address the question of whether this LTR
region has enhancer activity in the murine FDC-P1 progenitor cell line,
we have tested the ability of this enhancer to stimulate reporter gene
expression from a heterologous promoter in these promyelocytic cells.
We used the enhancer test plasmid pGL2-Promoter (Promega). Plasmid
pGL2-Promoter carries an enhancerless simian virus 40 (SV40) promoter
upstream of the luciferase reporter gene. DNA fragments containing
putative enhancer elements can be inserted in either orientation
upstream or downstream of the promoter-luciferase gene unit. Plasmid
pGL2-Promoter carrying the Mtv-1 LTR fragment from
nucleotides 6 to 556 (positions
1126 to
613 relative to the
position of the transcription start site in Mtv-1) either 5'
or 3' of the promoter-luciferase unit in either the plus or minus
orientation has been described (20). For our enhancer test
with FDC-P1 cells, we selected plasmid pGL2-E3+, which
contains the LTR fragment 3' of the promoter-luciferase unit in the
positive orientation. The position of the enhancer 3' of the luciferase
transcription unit was chosen to exclude contributions from potential
promoters within the fragment. Test plasmids were linearized within the
plasmid backbone with a restriction enzyme and used for transfection of
the mouse progenitor cell lines FDC-P1 (promyelocytic) and Ba/F3
(pro-B). Cells were harvested after 24 h and lysed. The luciferase
activity and protein concentration were determined from the lysate. We
found that the 548-bp enhancer fragment from positions
1162 to
613
of Mtv-1 stimulated gene expression in this assay system
from an enhancerless SV40 promoter in both Ba/F3 and FDC-P1 cells by
factors of 38 and 30, respectively (Fig.
2). We conclude that this enhancer is
similarly active in both Ba/F3 B-cell progenitor and FDC-P1
promyelocytic progenitor cells. The effect of this enhancer element in
primary hematopoietic progenitor cells remains to be tested.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Activity of the MMTV LTR enhancer in hematopoietic
progenitor cell lines. FDC-P1 and Ba/F3 cells were transfected either
in the absence of a reporter gene plasmid (mock) or with the enhancer
test plasmid pGL2-Promoter (pGL2-Pro) or pGL2-Pro containing the
Mtv-1 LTR fragment from positions 1162 to 613 cloned
into the unique BamHI site 3' of the promoter-reporter gene
cassette ( 1162 to 613). The schematic structure of the reporter
plasmid is shown below the graph. An enhancerless SV40 promoter
(PSV40) controls the expression of the luciferase reporter
gene (luc). The MMTV enhancer element is represented by an open box,
with an arrow indicating the positive orientation of the fragment. The
IL-3-dependent mouse progenitor cell lines Ba/F3 (16) and
FDC-P1 (5), gifts from U. Klingmüller, were maintained
in RPMI 1640 medium supplemented with 10% fetal calf serum, 10% WEHI
3B-conditioned medium, penicillin (100 IU/ml), and streptomycin (100 µg/ml). DNA was introduced by electroporation with a Bio-Rad
Genepulser. Equimolar amounts of test plasmids (2 pmol) were linearized
outside of the cloned provirus with a restriction enzyme. Carrier
plasmid pGEM-2 and TE (10 mM Tris, 1 mM EDTA [pH 7.0]) were added to
a constant DNA amount and volume. Cells were harvested after 24 h,
washed twice in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4), and lysed in reporter lysis buffer
(Promega). The luciferase assay system (Promega) was used for detection
of firefly luciferase (duplicate assays). Light emission was determined
for 10 s in a model ILA911 (Tropix) or a model Lumat LB 9501 (Berthold, Wildbad, Germany) luminometer. Protein concentration in
cellular extracts was measured by the Bio-Rad protein assay. Results
are expressed as relative light units and represent the arithmetic
means ± standard deviations from at least three parallel
experiments with two different DNA preparations.
|
|
The MMTV enhancer for B-cell progenitors is located within a 265-bp
region of the LTR and overlaps with a previously described mammary
gland cell enhancer.
Also within the MMTV LTR, mammary
gland-specific enhancer elements have been variously described at
positions
1075 to
978 (24), positions
1094 to
739
(14), positions
1180 to
902 (7), and
positions
1078 to
870 (12) of MMTV (strain C3H) (Fig.
1B). The different limits of this enhancer may derive from differences
in the levels of resolution of the individual analyses and the use of
different cell lines or assay systems by these investigators. This
enhancer promotes general MMTV gene expression in mammary epithelial
cells. The region of the MMTV (Mtv-1) LTR that we found to
be active as the transcription enhancer in the hematopoietic progenitor
cell lines Ba/F3 and FDC-P1 corresponds to positions
1186 to
638 of
MMTV(C3H) and includes all of the previously characterized mammary
gland enhancer elements. To determine the position of the newly
identified progenitor cell enhancer within the MMTV LTR and to answer
the question of whether the mammary gland and pro-B-cell enhancers are
separate entities, we selected the luciferase reporter plasmid pGL2-Pro
with the MMTV(Mtv-1) enhancer region (positions
1162 to
613) integrated 5' of the SV40 promoter luciferase reporter gene in
either the plus (pGL2-E5+) or minus (pGL2-E5
)
orientation (20). Relative enhancer strength in Ba/F3 cells was tested after analysis of progressive exonuclease deletion from the
5'-end-flanking plasmid region (Fig. 3).
We found that truncation from the 5' terminus up to position
1025 did
not affect reporter gene expression. Deletion to position
972
resulted in a partial loss (to 22%) and deletion to position
840 and
beyond resulted in a complete loss (
1%) of enhancer activity.
Removal of sequences from the 3' end to position
761 left enhancer
activity unchanged. A moderate reduction in enhancer activity to 46%
was noticed when the enhancer was shortened to position
838.
Truncation of the enhancer to position
893 and beyond resulted in a
complete loss of activity (
2%). These data suggest that a functional
pro-B-cell enhancer is present within a region from positions
1025 to
761 of the MMTV(Mtv-1) U3 region. The 5' limits of the
B-cell progenitor enhancer are found between positions
1025 and
972, and the 3' border is located between positions
761 and
838.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Localization of the MMTV pro-B-cell enhancer within the
Mtv-1 LTR by deletion analysis in Ba/F3 cells. The enhancer
test plasmid pGL2-Promoter with the Mtv-1 LTR fragment from
positions 1162 to 613 cloned into the unique XhoI site
5' of the promoter-reporter gene cassette in either the plus
(pGL2-E5+, filled squares) or minus (pGL2-E5 ,
open triangles) orientation and mutant plasmids with truncations to
positions 1025, 972, 840, 750, and 737 for
pGL2-E5+ and to positions 761, 838, 893, 969,
1096, and 1154 for pGL2-E5 were linearized with
BamHI and transfected into Ba/F3 cells by electroporation.
For each plasmid, a total of four transfections with two different
plasmid preparations was done. After 30 h, cells were harvested
and lysed and luciferase activity was determined as described in the
legend to Fig. 2. Results are expressed as relative light units and
represent the arithmetic means ± standard deviations from at
least three parallel experiments with two different DNA preparations.
Shown below the graph are a diagram of the MMTV (Mtv-1)
enhancer fragment from positions 1162 to 613 as described
previously (20) and a representation of the MMTV LTR with
the functional regions (U3, R, and U5), transcription start site (+1)
(labeled by a bent arrow), and restriction sites indicated. A hatched
box indicates the region required for full activity.
|
|
The MAF and NFI binding regions contribute to MMTV pro-B-cell
enhancer activity.
To test the hypothesis that the
MMTV(Mtv-1) LTR region from positions
1025 to
761
retains the full enhancer activity, we isolated the corresponding
region as a PCR-generated fragment and cloned this element between the
BamHI and SalI sites of the luciferase reporter
plasmid pGL2-Promoter. The resulting plasmid contained the potential
enhancer in a position 3' of the SV40 promoter luciferase gene reporter
unit (pGL2-E3+[
1025/
761]). When the enhancer activity
of this plasmid was compared to that of the pGL2-E3+
plasmid, which includes the original enhancer (positions
1162 to
613), in Ba/F3 cells, no significant difference was observed (Fig.
4A). We conclude from this experiment,
that a fully functional pro-B-cell enhancer is located within a region
from positions
1025 to
761 of the MMTV(Mtv-1) LTR. This
region corresponds to positions
1049 to
785 of MMTV(C3H) and is
largely identical to the mammary gland-specific enhancer previously
characterized independently by four different laboratories (7, 12,
14, 24) (Fig. 1B). The B-cell progenitor enhancer region
identified here is separate from the glucocorticoid response elements
at positions
202 to
52. It contains the previously identified
binding sites for mammary cell-activating factor (MAF) and CTF (also
called NFI) (14) (Fig. 4B), which are involved in enhancer
activity in mammary gland cells. MAF is an Ets-related transcription
factor (23) and binds at two sites within the enhancer (Fig.
4B).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 4.
A 265-bp region from the Mtv-1 LTR is sufficient as an
enhancer in Ba/F3 cells. (A) Ba/F3 cells were transfected without added
reporter plasmid DNA (mock) or with the enhancer test plasmid pGL2-Pro
or pGL2-Pro carrying the Mtv-1 regions indicated cloned into
the unique BamHI and SalI sites 3' of the
promoter-reporter cassette. Cells were harvested and lysed, and
luciferase activity was determined. Results are expressed as relative
light units and represent the arithmetic means ± standard
deviations from at least three parallel experiments with two different
DNA preparations. PSV40, SV40 promoter (solid square). The
NFI (solid oval) and MAF (open oval) sites are shown. (B) The DNA
sequence of the Mtv-1 LTR region (8) from
positions 1025 to 761 is presented below the graph. Established NFI
and MAF binding sites (14) are shown by dashed and solid
ovals, respectively.
|
|
The truncation analysis results shown in Fig.
3 suggest an important
role for the 3' MAF binding site: loss of the region
between positions

838 and

893, including this MAF binding site,
drastically reduced
enhancer activity from 46% to less than 1%
of the intact enhancer.
The NFI and MAF sites at the 5' end of
the enhancer are not sufficient
to maintain detectable enhancer
activity. To specifically test the
contribution of the MAF and
NFI transcription factor binding sites at
the 5' terminus of the
element to enhancer activity in pro-B cells, we
successively removed
these two sites (Fig.
4). We found that enhancer
elements truncated
in steps to position

976 showed gradually reduced
enhancer activity
(Fig.
4). In this analysis the loss of the region
from

1025 to

998 that includes the NFI interaction site had only a
minor effect.
Further truncation to position

987 near the MAF binding
site
or removal of this site after deletion to position

976 reduced
activity from 88 to 68 or 35%, respectively. The region from positions

976 to

761 that included only the 3' MAF site still retained
35%
of the maximal activity. This is in good agreement with our
previous
results shown in Fig.
3, where truncation from the 5'
terminus to
position

972 was found to reduce enhancer activity
to 22%.
We conclude that the MMTV transcription enhancer for B-cell progenitor
and possibly also myeloid progenitor cells largely
colocalizes with a
previously characterized MMTV mammary gland
enhancer (Fig.
1B). Both
enhancers share specific functional regions
that include the previously
described NFI and MAF binding sites.
Regions including the NFI and MAF
binding sites at the 5' end
of the enhancer had a weak-to-moderate
effect, while the region
surrounding the 3' MAF binding site had a
strong effect on enhancer
activity.
The MMTV
sag gene within the LTR encodes isolate-specific
superantigens that activate specific T-cell populations when they
are
expressed on the surfaces of antigen-presenting cells (
1).
Our previous screen for functional elements within the MMTV provirus
that mediate
sag gene expression demonstrated, surprisingly,
that
promoters within the 5' LTR are not required for
sag
gene expression
in B-lymphoid cell lines (
19,
20). By
contrast, expression
of the MMTV
sag gene in the mouse pro-B
cell line Ba/F3 depends
on an enhancer element within the viral U3
region (
20). We demonstrate
now that this enhancer is
similarly active in a nonlymphoid hematopoietic
progenitor cell line,
FDC-P1, which is committed in its differentiation
capacity to the
myeloid cell lineage that includes monocytes/macrophages,
granulocytes,
platelets, and erythrocytes (
5). These data suggest
that the
observed expression of the MMTV
sag gene and the production
of MMTV virions in FDC-P1 cells (Tovar Sepulveda et al., submitted)
is
regulated by the effect of the MMTV LTR enhancer in the LTR
on
individual promoters. For
sag expression, our data indicate
that a non-LTR promoter is used (Tovar Sepulveda et al., submitted),
but the effect of the LTR enhancer on
sag expression in
these
cells has not directly been tested yet. It is interesting that
monocytes and macrophages are antigen-presenting cells and express
the
major histocompatibility complex class II antigens required
for MMTV
superantigen activity. MMTV transmission requires the
presence of B
cells, but MMTV superantigen presentation, T-cell
stimulation, and
T-cell deletion are possible in the absence of
B cells (
2).
The non-B antigen-presenting cells that are able
to mediate the
superantigen effect have not yet been identified,
but the involvement
of myeloid cell types appears
likely.
The MMTV transcription enhancer for pro-B cells maps to the region from
positions

1025 to

761 of the MMTV(
Mtv-1) LTR
(
4).
This region corresponds to positions

1049 to

785 of
MMTV(C3H)
(
13). The DNA sequences of the endogenous provirus
Mtv-1 and
the exogenous C3H virus isolate in this region
differ in eight
positions scattered throughout the region. As
previously shown,
there are no strain-specific differences with respect
to enhancer
activity between the
Mtv-1 and C3H- LTRs in
Ba/F3 B-cell progenitor
cells (
20). A region from the
MMTV(C3H) LTR that contains this
enhancer element has the same
stimulatory effect on
sag gene expression
in the context of
our hybrid MMTV reporter
provirus.
The B-cell progenitor enhancer described here largely colocalizes with
the mammary gland-specific enhancer previously characterized
by four
independent laboratories (
7,
12,
14,
24) of the
MMTV (C3H)
LTR. Specifically, the MMTV enhancer for gene expression
in pro-B cells
contains the previously identified binding sites
for MAF and NFI
(
14) (Fig.
4B). The regions surrounding the
NFI, 5' MAF, and
3' MAF binding sites have only a weak, a moderate,
and a strong effect
on enhancer activity in Ba/F3 cells, respectively.
At the 3' border of
the enhancer, still uncharacterized functional
elements downstream of
the MAF site have a moderate effect on
enhancer function. These data
suggest that functional elements
are shared between the mammary gland
cell and B-cell progenitor
enhancers. The involvement of additional
transcription factors
and binding sites for enhancer activity in
hematopoietic progenitors
is possible. Additionally, the specificity of
MMTV gene expression
may be influenced by regulatory elements outside
the previously
characterized mammary gland and progenitor cell
enhancers (
18).
 |
ACKNOWLEDGMENTS |
We are grateful to H. zur Hausen for support, to U. Klingmüller and H. Varmus for generous gifts of cell lines or
reagents, and to S. Fenner for technical assistance.
J.M.C. is an American Cancer Society professor of molecular biology and
microbiology. This work was supported by National Cancer Institute
award R35CA44385 to J.M.C. and a Leukemia Society of America fellowship
to F.U.R.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Deutsches
Krebsforschungszentrum, Forschungsschwerpunkt Angewandte
Tumorvirologie F0400, Im Neuenheimer Feld 242, 69120 Heidelberg,
Germany. Phone: 49-6221-424657. Fax: 49-6221-424902. E-mail:
f.reuss{at}dkfz-heidelberg.de.
 |
REFERENCES |
| 1.
|
Acha Orbea, H., and H. R. MacDonald.
1995.
Superantigens of mouse mammary tumor virus.
Annu. Rev. Immunol.
13:459-486[CrossRef][Medline].
|
| 2.
|
Beutner, U.,
E. Kraus,
D. Kitamura,
K. Rajewsky, and B. T. Huber.
1994.
B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens.
J. Exp. Med.
179:1457-1466[Abstract/Free Full Text].
|
| 3.
|
Bittner, J. J.
1936.
Some possible effects of nursing on the mammary gland tumor incidence in mice.
Science
84:162-169[Free Full Text].
|
| 4.
|
Crouse, C. A., and R. J. Pauley.
1989.
Molecular cloning and sequencing of the MTV-1 LTR: evidence for a LTR sequence alteration.
Virus Res.
12:123-137[CrossRef][Medline].
|
| 5.
|
Dexter, T. M.,
J. Garland,
D. Scott,
E. Scolnick, and D. Metcalf.
1980.
Growth of factor-independent hemopoietic precursor cell lines.
J. Exp. Med.
152:1036-1047[Abstract/Free Full Text].
|
| 6.
|
Frankel, W. N.,
C. Rudy,
J. M. Coffin, and B. T. Huber.
1991.
Linkage of Mls genes to endogenous mammary tumor viruses of inbred mice.
Nature
349:526-528[CrossRef][Medline].
|
| 7.
|
Gouilleux, F.,
B. Sola,
B. Couette, and H. Richard Foy.
1991.
Cooperation between structural elements in hormono-regulated transcription from the mouse mammary tumor virus promoter.
Nucleic Acids Res.
19:1563-1569[Abstract/Free Full Text].
|
| 8.
|
Hainaut, P.,
D. Vaira,
C. Francois,
B. C. M. Calberg, and P. M. Osterrieth.
1985.
Natural infection of Swiss mice with mouse mammary tumor virus (MMTV): viral expression in milk and transmission of infection.
Arch. Virol.
83:195-206[CrossRef][Medline].
|
| 9.
|
Held, W.,
A. N. Shakhov,
S. Izui,
G. A. Waanders,
L. Scarpellino,
H. R. MacDonald, and H. Acha Orbea.
1993.
Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.
J. Exp. Med.
177:359-366[Abstract/Free Full Text].
|
| 10.
|
Held, W.,
G. A. Waanders,
A. N. Shakhov,
L. Scarpellino,
H. Acha Orbea, and H. R. MacDonald.
1993.
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission.
Cell
74:529-540[CrossRef][Medline].
|
| 11.
|
Kappler, J. W.,
U. Staerz,
J. White, and P. C. Marrack.
1988.
Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex.
Nature
332:35-40[CrossRef][Medline].
|
| 12.
|
Lefebvre, P.,
D. S. Berard,
M. G. Cordingley, and G. L. Hager.
1991.
Two regions of the mouse mammary tumor virus long terminal repeat regulate the activity of its promoter in mammary cell lines.
Mol. Cell. Biol.
11:2529-2537[Abstract/Free Full Text].
|
| 13.
|
Majors, J. E., and H. E. Varmus.
1983.
Nucleotide sequencing of an apparent proviral copy of env mRNA defines determinants of expression of the mouse mammary tumor virus env gene.
J. Virol.
47:495-504[Abstract/Free Full Text].
|
| 14.
|
Mink, S.,
E. Hartig,
P. Jennewein,
W. Doppler, and A. C. Cato.
1992.
A mammary cell-specific enhancer in mouse mammary tumor virus DNA is composed of multiple regulatory elements including binding sites for CTF/NFI and a novel transcription factor, mammary cell-activating factor.
Mol. Cell. Biol.
12:4906-4918[Abstract/Free Full Text].
|
| 15.
|
Nandi, S., and C. M. McGrath.
1973.
Mammary neoplasia in mice.
Adv. Cancer Res.
17:353-414.
|
| 16.
|
Palacios, R., and M. Steinmetz.
1985.
Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.
Cell
41:727-734[CrossRef][Medline].
|
| 17.
|
Pullen, A. M.,
T. Wade,
P. Marrack, and J. W. Kappler.
1990.
Identification of the region of T cell receptor beta chain that interacts with the self-superantigen MIs-1a.
Cell
61:1365-1374[CrossRef][Medline].
|
| 18.
|
Qin, W.,
T. V. Golovkina,
T. Peng,
I. Nepomnaschy,
V. Buggiano,
I. Piazzon, and S. R. Ross.
1999.
Mammary gland expression of mouse mammary tumor virus is regulated by a novel element in the long terminal repeat.
J. Virol.
73:368-376[Abstract/Free Full Text].
|
| 19.
|
Reuss, F. U., and J. M. Coffin.
1998.
Mouse mammary tumor virus superantigen expression in B cells is regulated by a central enhancer within the pol gene.
J. Virol.
72:6073-6082[Abstract/Free Full Text].
|
| 20.
|
Reuss, F. U., and J. M. Coffin.
1995.
Stimulation of mouse mammary tumor virus superantigen expression by an intragenic enhancer.
Proc. Natl. Acad. Sci. USA
92:9293-9297[Abstract/Free Full Text].
|
| 21.
|
Shackleford, G. M., and H. E. Varmus.
1988.
Construction of a clonable, infectious, and tumorigenic mouse mammary tumor virus provirus and a derivative genetic vector.
Proc. Natl. Acad. Sci. USA
85:9655-9659[Abstract/Free Full Text].
|
| 22.
|
Tsiagbe, V. K.,
T. Yoshimoto,
J. Asakawa,
S. Y. Cho,
D. Meruelo, and G. J. Thorbecke.
1993.
Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus.
EMBO J.
12:2313-2320[Medline].
|
| 23.
|
Welte, T.,
K. Garimorth,
S. Philipp,
P. Jennewein,
C. Huck,
A. C. Cato, and W. Doppler.
1994.
Involvement of Ets-related proteins in hormone-independent mammary cell-specific gene expression.
Eur. J. Biochem.
223:997-1006[Medline].
|
| 24.
|
Yanagawa, S.-I.,
H. Tanaka, and A. Ishimoto.
1991.
Identification of a novel mammary cell line-specific enhancer element in the long terminal repeat of mouse mammary tumor virus, which interacts with its hormone-responsive element.
J. Virol.
65:526-531[Abstract/Free Full Text].
|
Journal of Virology, September 2000, p. 8183-8187, Vol. 74, No. 17
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Morabito, J. E, Trott, J. F, Korz, D. M, Fairfield, H. E, Buck, S. H, Hovey, R. C
(2008). A 5' distal palindrome within the mouse mammary tumor virus-long terminal repeat recruits a mammary gland-specific complex and is required for a synergistic response to progesterone plus prolactin. J Mol Endocrinol
41: 75-90
[Abstract]
[Full Text]
-
Rouault, F., Nejad Asl, S. B., Rungaldier, S., Fuchs, E., Salmons, B., Gunzburg, W. H.
(2007). Promoter Complex in the Central Part of the Mouse Mammary Tumor Virus Long Terminal Repeat. J. Virol.
81: 12572-12581
[Abstract]
[Full Text]
-
Kappeler, S. R., Farah, Z., Puhan, Z.
(2003). 5'-Flanking Regions of Camel Milk Genes Are Highly Similar to Homologue Regions of Other Species and Can be Divided into Two Distinct Groups. J DAIRY SCI
86: 498-508
[Abstract]
[Full Text]
-
Reuss, F. U., Berdel, B., Ploss, M., Heber, R.
(2001). Replication of enhancer-deficient amphotropic murine leukemia virus in human cells. Proc. Natl. Acad. Sci. USA
10.1073/pnas.191182098v1
[Abstract]
[Full Text]
-
Reuss, F. U., Berdel, B., Ploss, M., Heber, R.
(2001). Replication of enhancer-deficient amphotropic murine leukemia virus in human cells. Proc. Natl. Acad. Sci. USA
98: 10898-10903
[Abstract]
[Full Text]